Azole Binding Properties of Candida albicans Sterol 14-α Demethylase (CaCYP51)
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Purified Candida albicans sterol 14-α demethylase (CaCYP51) bound the CYP51 substrates lanosterol and eburicol, producing type I binding spectra with K s values of 11 and 25 μM, respectively, and a K m value of 6 μM for lanosterol. Azole binding to CaCYP51 was “tight” with both the type II spectral intensity (Δ A max ) and the azole concentration required to obtain a half-Δ A max being proportional to the CaCYP51 concentration. Tight binding of fluconazole and itraconazole was confirmed by 50% inhibitory concentration determinations from CYP51 reconstitution assays. CaCYP51 had similar affinities for clotrimazole, econazole, itraconazole, ketoconazole, miconazole, and voriconazole, with K d values of 10 to 26 μM under oxidative conditions, compared with 47 μM for fluconazole. The affinities of CaCYP51 for fluconazole and itraconazole appeared to be 4- and 2-fold lower based on CO displacement studies than those when using direct ligand binding under oxidative conditions. Econazole and miconazole were most readily displaced by carbon monoxide, followed by clotrimazole, ketoconazole, and fluconazole, and then voriconazole (7.8 pmol min −1 ), but itraconzole could not be displaced by carbon monoxide. This work reports in depth the characterization of the azole binding properties of wild-type C. albicans CYP51, including that of voriconazole, and will contribute to effective screening of new therapeutic azole antifungal agents. Preliminary comparative studies with the I471T CaCYP51 protein suggested that fluconazole resistance conferred by this mutation was through a combination of increased turnover, increased affinity for substrate, and a reduced affinity for fluconazole in the presence of substrate, allowing the enzyme to remain functionally active, albeit at reduced velocity, at higher fluconazole concentrations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Point mutations in the ERG11 gene result in reduced binding affinity of azoles to their target without precluding enzymatic function (31).”
From Gain-of-Function Mutations in UPC2 Are a Frequent Cause of ERG11 Upregulation in Azole-Resistant Clinical Isolates of Candida albicans (2012) · cites this paper as [31]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Carbon Monoxide-binding Pigment of Liver Microsomes
Omura, T., & Sato, R. (1964) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)82244-3 · Cited by 11,781
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 1×
“albicans strains and other Candida species has become an increasing problem, especially among hospitalized immunocompromised patients, such as HIV and AIDS, cancer, and transplant patients, leading to a growing need to develop new effective antifungal strategies against drug-resistant strains (41, 45, 49).”
BackgroundThe Carbon Monoxide-binding Pigment of Liver Microsomes
Omura, T., & Sato, R. (1964) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)82245-5 · Cited by 3,489
Copeland, R. A. (2005) · PubMed · Cited by 1,092
Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors
Morrison, J. F. (1969) · Biochimica et Biophysica Acta (BBA) - Enzymology · doi:10.1016/0005-2744(69)90420-3 · Cited by 814 · cited 4×
“The data were fitted using the Morrison equation (37), including a vertical offset constant where appropriate to determine the apparent Kd values.”
BackgroundMethodInfluentialPodust, L. M., Poulos, T. L., & Waterman, M. R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.061562898 · Cited by 531 · cited 2×
“The I471T residue lies in the cysteine pocket behind the plane of the heme and therefore cannot directly interact with the substrate or inhibitor (44).”
BackgroundChanging patterns and trends in systemic fungal infections
Richardson, M. D. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki218 · Cited by 525 · cited 1×
“albicans strains and other Candida species has become an increasing problem, especially among hospitalized immunocompromised patients, such as HIV and AIDS, cancer, and transplant patients, leading to a growing need to develop new effective antifungal strategies against drug-resistant strains (41, 45, 49).”
BackgroundSterol 14α-demethylase cytochrome P450 (CYP51), a P450 in all biological kingdoms
Lepesheva, G. I., & Waterman, M. R. (2007) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2006.07.018 · Cited by 474 · cited 1×
“This network would strengthen the water-iron coordination, explaining why CYP51 proteins are found predominantly in the low-spin form (29) and why CYP51 proteins undergo only a partial low- to high-spin transition during substrate binding.”
BackgroundSanglard, D., Ischer, F., Koymans, L., & Bille, J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.2.241 · Cited by 465 · cited 1×
“By building on this comprehensive investigation of clinically relevant azoles and their binding properties to purified wild-type CaCYP51, we are currently investigating the effects of CaCYP51 point mutations associated with azole resistance (9, 30, 32, 34, 47, 54, 56).”
BackgroundMarichal, P., Koymans, L., Willemsens, S., Bellens, D., Verhasselt, P., Luyten, W., Borgers, M., Ramaekers, F. C. S., Odds, F. C., & Vanden Bossche, H. (1999) · Microbiology · doi:10.1099/00221287-145-10-2701 · Cited by 382 · cited 1×
“By building on this comprehensive investigation of clinically relevant azoles and their binding properties to purified wild-type CaCYP51, we are currently investigating the effects of CaCYP51 point mutations associated with azole resistance (9, 30, 32, 34, 47, 54, 56).”
Background
Cited by
Fluconazole resistance in Candida species: a current perspective
Berkow, E., & Lockhart, S. (2017) · Infection and Drug Resistance · doi:10.2147/idr.s118892 · Cited by 542
Contribution of Clinically Derived Mutations in ERG11 to Azole Resistance in Candida albicans
Flowers, S. A., Colón, B., Whaley, S. G., Schuler, M. A., & Rogers, P. D. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03470-14 · Cited by 294
Triazole Antifungal Agents in Invasive Fungal Infections: A Comparative Review
Lass-Flörl, C. (2011) · Drugs · doi:10.2165/11596540-000000000-00000 · Cited by 270
“Adverse events associated with the various triazoles([1-4,24-26,31,32])”
BackgroundBecher, R., & Wirsel, S. G. R. (2012) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-012-4195-9 · Cited by 245
“…Park et al. 2011), F145L (Bellamine et al. 2004; Kudo et al. 2005), T315A (Lamb et al. 1997), G464S (Kelly et al. 1999), R467K (Lamb et al. 2000; Park et al. 2011; White 1997), I471T (Warrilow et al. 2010), or multiple substitutions (Bellamine et al. 2004; Kudo et al. 2005; Marichal et al. 1999).”
BackgroundInfluentialFlowers, S. A., Barker, K. S., Berkow, E. L., Toner, G., Chadwick, S. G., Gygax, S. E., Morschhäuser, J., & Rogers, P. D. (2012) · Eukaryotic Cell · doi:10.1128/ec.00215-12 · Cited by 239
“Point mutations in the ERG11 gene result in reduced binding affinity of azoles to their target without precluding enzymatic function (31).”
BackgroundKelly, S. L., & Kelly, D. E. (2013) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2012.0476 · Cited by 230
Self-citationSagatova, A. A., Keniya, M. V., Wilson, R. K., Monk, B. C., & Tyndall, J. D. A. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00925-15 · Cited by 210
“5 values were found to be about half the P450 concentration values, indicating tight binding for VCZ and FLC (31, 41).”
BackgroundInfluentialResistance to antifungals that target CYP51
Parker, J. E., Warrilow, A. G. S., Price, C. L., Mullins, J. G. L., Kelly, D. E., & Kelly, S. L. (2014) · Journal of Chemical Biology · doi:10.1007/s12154-014-0121-1 · Cited by 204
“In contrast, I471T had nearly a 3fold lower Ks value than the wild-type enzyme, and this did result in more than 2-fold increase in reaction velocity [90, 91].”
BackgroundInfluentialSelf-citationAzole Affinity of Sterol 14α-Demethylase (CYP51) Enzymes from Candida albicans and Homo sapiens
Warrilow, A. G., Parker, J. E., Kelly, D. E., & Kelly, S. L. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02067-12 · Cited by 152
“CaCYP51 using truncated 33 Saccharomyces cerevisiae CPR (4), sug-”
BackgroundMethodResultSelf-citationSteroid-transforming enzymes in fungi
Kristan, K., & Rižner, T. L. (2011) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2011.08.012 · Cited by 167
Fungal Lanosterol 14α-demethylase: A target for next-generation antifungal design
Monk, B. C., Sagatova, A. A., Hosseini, P., Ruma, Y. N., Wilson, R. K., & Keniya, M. V. (2019) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2019.02.008 · Cited by 168
Molecular Mechanisms of Drug Resistance in Clinical Candida Species Isolated from Tunisian Hospitals
Eddouzi, J., Parker, J. E., Vale-Silva, L. A., Coste, A., Ischer, F., Kelly, S., Manai, M., & Sanglard, D. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00555-13 · Cited by 128
Self-citationLestner, J., & Hope, W. W. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.794785 · Cited by 128
“This reaction is also inhibited by carbon monoxide (CO) [32].”
BackgroundHargrove, T. Y., Wawrzak, Z., Liu, J., Nes, W. D., Waterman, M. R., & Lepesheva, G. I. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.237099 · Cited by 137
Self-citationSagatova, A. A., Keniya, M. V., Wilson, R. K., Sabherwal, M., Tyndall, J. D. A., & Monk, B. C. (2016) · Scientific Reports · doi:10.1038/srep26213 · Cited by 117
Molecular Mechanisms of Action of Herbal Antifungal Alkaloid Berberine, in Candida albicans
Dhamgaye, S., Devaux, F., Vandeputte, P., Khandelwal, N. K., Sanglard, D., Mukhopadhyay, G., & Prasad, R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104554 · Cited by 101
“Each of these classes of antifungals have a distinct mode of action, for example azoles target heme protein, cytochrome P450 lanosterol 14 a demethylase thereby impeding conversion of lanosterol to fecosterol and subsequently blocking ergosterol biosynthesis [4].”
BackgroundThe role of azoles in the management of azole-resistant aspergillosis: From the bench to the bedside
Seyedmousavi, S., Mouton, J. W., Melchers, W. J. G., Brüggemann, R. J. M., & Verweij, P. E. (2014) · Drug Resistance Updates · doi:10.1016/j.drup.2014.06.001 · Cited by 107
Apigenin-7-O-glucoside versus apigenin: insight into the modes of anticandidal and cytotoxic actions
Smiljkovic, M. S., Stanisavljevic, D., Stojković, D. S., Petrović, I., Vićentić, J. M., Popovic, J., Grdadolnik, S. G., Markovic, D. L. J., Sankovic‐Babic, S., Glamočlija, J., et al. (2017) · EXCLI journal · doi:10.17179/excli2017-300 · Cited by 99
“AP7Glu and apigenin do not show binding affinities to candidal CYP51 protein CYP51 is enzyme essential for Candida albicans involved in ergosterol biosynthetic pathway, and it’s main target for azole antifungal drugs (Kelly et al., 2003; Warrilow et al., 2010).”
BackgroundBerkow, E. L., Manigaba, K., Parker, J. E., Barker, K. S., Kelly, S. L., & Rogers, P. D. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01358-15 · Cited by 95
“Also, mutations in ERG11 that lead to amino acid substitutions alter target protein structures, reduce drug binding affinity, and increase azole resistance (10).”
BackgroundSelf-citationParker, J. E., Warrilow, A. G. S., Cools, H. J., Fraaije, B. A., Lucas, J. A., Rigdova, K., Griffiths, W. J., Kelly, D. E., & Kelly, S. L. (2013) · Applied and Environmental Microbiology · doi:10.1128/aem.03246-12 · Cited by 94
“albicans enzyme systems previously used for in vitro studies (9) to elucidate the effects observed in whole-cell treatments of C.”
MethodResultInfluentialSelf-citationWarrilow, A. G. S., Melo, N., Martel, C. M., Parker, J. E., Nes, W. D., Kelly, S. L., & Kelly, D. E. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00316-10 · Cited by 85
Self-citationKelly, A. C., Proctor, R. H., Belzile, F. J., Chulze, S., Clear, R. M., Cowger, C., Elmer, W. H., Lee, T., Obanor, F. O., Waalwijk, C., et al. (2016) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2016.08.003 · Cited by 100
Candida albicans targets that potentially synergize with fluconazole
Lu, H., Shrivastava, M., Whiteway, M., & Jiang, Y. (2021) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2021.1884641 · Cited by 81
“Fluconazole blocks the ergosterol biosynthetic pathway in both Saccharomyces cerevisiae (Sagatova et al. 2015) and C. albicans (Warrilow et al. 2010; Hargrove et al. 2017), by directly inhibiting lanosterol 14a-demethylase (Erg11), the enzyme that catalyzes the oxidative removal of the 14a-methyl…”
BackgroundWarrilow, A. G. S., Parker, J. E., Price, C. L., Nes, W. D., Garvey, E. P., Hoekstra, W. J., Schotzinger, R. J., Kelly, D. E., & Kelly, S. L. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00349-16 · Cited by 75
Self-citationTherapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis
Seyedmousavi, S., Mouton, J. W., Verweij, P. E., & Brüggemann, R. J. M. (2013) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2013.826989 · Cited by 79
Gatfaoui, S., Issaoui, N., Mezni, A., Bardak, F., Roisnel, T., Ataç, A., & Marouani, H. (2017) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2017.08.092 · Cited by 68
Doğan, İ. S., Saraç, S., Sarı, S., Kart, D., Essiz, S. G., Vural, İ., & Dalkara, S. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.02.035 · Cited by 69
Systemic Antifungal Agents: Current Status and Projected Future Developments
Seyedmousavi, S., Rafati, H., İlkit, M., Tolooe, A., Hedayati, M. T., & Verweij, P. E. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6515-1_5 · Cited by 68
Warrilow, A. G., Nishimoto, A. T., Parker, J. E., Price, C. L., Flowers, S. A., Kelly, D. E., Rogers, P. D., & Kelly, S. L. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02586-18 · Cited by 60
Self-citationMishra, S. K., Shankar, U., Jain, N., Sikri, K., Tyagi, J. S., Sharma, T. K., Mergny, J., & Kumar, A. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.04.022 · Cited by 58
Warrilow, A. G. S., Hull, C. M., Rolley, N. J., Parker, J. E., Nes, W. D., Smith, S. N., Kelly, D. E., & Kelly, S. L. (2014) · Applied and Environmental Microbiology · doi:10.1128/aem.01195-14 · Cited by 61
“were identical to those previously reported (39).”
Self-citationCytotoxicity of Voriconazole on Cultured Human Corneal Endothelial Cells
Han, S. B., Shin, Y. J., Hyon, J. Y., & Wee, W. R. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00569-11 · Cited by 54
“This antifungal agent is a synthetic derivative of fluconazole modified by adding a methyl group to the propyl backbone and by substituting a triazole moiety with a fluoropyrimidine group; this results in a higher affinity for fungal 14- -demethylase, leading to more potent activities and excellent efficacy in patient…”
BackgroundConte, M., Lupette, J., Seddiki, K., Meï, C., Dolch, L.-J., Gros, V., Barette, C., Rébeillé, F., Jouhet, J., & Maréchal, É. (2018) · PLANT PHYSIOLOGY · doi:10.1104/pp.17.01804 · Cited by 58
Chatzimoschou, A., Katragkou, A., Simitsopoulou, M., Antachopoulos, C., Georgiadou, E., Walsh, T. J., & Roilides, E. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00959-10 · Cited by 55
“The exact reason for this phenomenon is not known; however, it could be attributed to the different properties of azole binding to different Candida cells (37).”
BackgroundIsavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases
Seyedmousavi, S., Verweij, P. E., & Mouton, J. W. (2014) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2015.990382 · Cited by 54
“The various triazoles have different affinities for the CYP-dependent 14-a-demethylase, which in turn results in various antifungal activities [28] and therefore various susceptibilities of fungi.”
BackgroundChen, S., Wang, Y., Schnabel, G., Peng, C. A., Lagishetty, S., Smith, K. S., Luo, C., & Yuan, H. (2018) · Phytopathology · doi:10.1094/phyto-02-18-0054-r · Cited by 59
Zheng, B., Yan, L., Liang, W., & Yang, Q. (2018) · Pest Management Science · doi:10.1002/ps.5127 · Cited by 43
Anti-Candida albicans Activity of Ononin and Other Secondary Metabolites from Platonia Insignis MART
da Silva, A. F., Farias, J. R., Franco, D. C. G., Galiza, A. A., Motta, E. P., Oliveira, A. D. S., Vasconcelos, C. C., Cartágenes, M. D. S. D. S., da Rocha, C. Q., Silva, M. C. P. D., et al. (2022) · Metabolites · doi:10.3390/metabo12111014 · Cited by 38
“This has become a growing problem, especially among immunocompromised individuals, such as transplant patients, patients with cancer, and HIV/AIDS patients [50]; for this reason, there is an urgent need to develop new effective therapeutic strategies against these strains that are resistant to conventional antifungals.”
BackgroundInteraction of Human Drug-Metabolizing CYP3A4 with Small Inhibitory Molecules
Sevrioukova, I. F. (2019) · Biochemistry · doi:10.1021/acs.biochem.8b01221 · Cited by 40
Genomic Multiplication and Drug Efflux Influence Ketoconazole Resistance in Malassezia restricta
Park, M., Cho, Y., Lee, Y. W., & Jung, W. H. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00191 · Cited by 41
“Mutations in the coding region of the gene result in amino acid substitutions, which alter the structure of the enzyme and reduce the affinity of the target for the azole (Sanglard et al., 1998; Warrilow et al., 2010).”
BackgroundAlvarez-Rueda, N., Fleury, A., Morio, F., Pagniez, F., Gastinel, L., & Le Pape, P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021239 · Cited by 34
“Interestingly, the Y447H mutant is characterized by FLC resistance but remains highly susceptible to voriconazole which has the best Kd value for the wild-type CaCYP51 protein [49].”
BackgroundChen, S., Hu, M., Schnabel, G., Yang, D., Yan, X., & Yuan, H. (2019) · Phytopathology · doi:10.1094/phyto-10-19-0385-r · Cited by 33
Sagatova, A. A., Keniya, M. V., Tyndall, J. D. A., & Monk, B. C. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02242-17 · Cited by 33
“ScErg11p6 His used for spectroscopic assays was affinity purified as described previously (38), using 50 mM L-histidine rather than imidazole for elution in affinity purification buffer.”
MethodWarrilow, A. G. S., Mullins, J. G. L., Hull, C. M., Parker, J. E., Lamb, D. C., Kelly, D. E., & Kelly, S. L. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05389-11 · Cited by 30
“nmol per liter of culture was comparable to those obtained previously (5, 23, 49).”
MethodResultSelf-citationWarrilow, A. G. S., Parker, J. E., Price, C. L., Garvey, E. P., Hoekstra, W. J., Schotzinger, R. J., Wiederhold, N. P., Nes, W. D., Kelly, D. E., & Kelly, S. L. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00333-17 · Cited by 33
Self-citationPXR as the tipping point between innate immune response, microbial infections, and drug metabolism
Bautista-Olivier, C. D., & Elizondo, G. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115147 · Cited by 30
Topical and systemic antifungals in dermatology practice
Durdu, M., İlkit, M., Tamaddon, Y., Tolooe, A., Rafati, H., & Seyedmousavi, S. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1263564 · Cited by 34
“The triazoles have different affinities for the CYPdependent 14-a-demethylase, which in turn results in variability of the susceptibilities to fungal infection, side effects, and drug–drug interactions [83].”
BackgroundSynthesis and Anticandidal Activity Evaluation of New Benzimidazole-Thiazole Derivatives
Kaplancıklı, Z. A., Levent, S., Osmaniye, D., Sağlık, B. N., Çevik, U. A., Kaya, B., Özkay, Y., & Ilgın, S. (2017) · Molecules · doi:10.3390/molecules22122051 · Cited by 30
“The mechanism of action of azole antifungals involves the direct coordination of nucleophilic nitrogen of the azole heterocyclic ring to the sixth ligand of the heme ferric ion, and interactions of the azole drug side chains with the CYP51 polypeptide structure [13,14].”
Gale, A. N., Pavesic, M. W., Nickels, T. J., Xu, Z., Cormack, B. P., & Cunningham, K. W. (2023) · mSphere · doi:10.1128/msphere.00254-23 · Cited by 27
Econazole Induces p53-Dependent Apoptosis and Decreases Metastasis Ability in Gastric Cancer Cells
Choi, E. K., Park, E. J., Phan, T. T., Kim, H. D., Hoe, K., & Kim, D.-U. (2020) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2019.201 · Cited by 27
Liao, Z., Yan, Y., Dong, H., Zhu, Z., Jiang, Y., & Cao, Y. (2016) · Emerging Microbes & Infections · doi:10.1038/emi.2016.87 · Cited by 30
Potent Antifungal Synergy of Phthalazinone and Isoquinolones with Azoles Against Candida albicans
Mood, A. D., Premachandra, I. D. U. A., Hiew, S. C., Wang, F., Scott, K. A., Oldenhuis, N. J., Liu, H., & Vranken, D. L. V. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00355 · Cited by 31
Vu, B. G., & Moye-Rowley, S. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02098-21 · Cited by 33
Vitamin D3 a new drug against Candida albicans
Djihane, B., Merzouki, S., Bachiri, M., Ailane, S. E., & Zerroug, M. M. (2016) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2016.10.003 · Cited by 26
Park, H., Lee, I., Chun, Y., Yun, C., Johnston, J. B., de Montellano, P. R. O., & Kim, D. (2011) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2011.02.002 · Cited by 25
Hoobler, E. K., Rai, G., Warrilow, A. G. S., Perry, S., Smyrniotis, C. J., Jadhav, A., Simeonov, A. M., Parker, J. E., Kelly, D. E., Maloney, D. J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065928 · Cited by 25
“Ketoconazole and ketaminazole (16) both bound tightly to CaCYP51 with Kd values of 2765 and 4365 nM, respectively.”
MethodResultInfluentialSelf-citationInhibitory effects of deoxynivalenol on pathogenesis of Candida albicans
Rajasekharan, S. K., Byun, J., & Lee, J. (2018) · Journal of Applied Microbiology · doi:10.1111/jam.14032 · Cited by 25
“Azole drugs function by inhibiting lanosterol 14a-demethylase, thus causing fungal death (Warrilow et al. 2010).”
BackgroundTranscriptomics Analysis of Candida albicans Treated with Huanglian Jiedu Decoction Using RNA‐seq
Yang, Q., Gao, L., Tao, M., Chen, Z., Yang, X., & Cao, Y. (2016) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2016/3198249 · Cited by 24
“…13 November 2015; Accepted 21 March 2016 Academic Editor: Letizia Angiolella Copyright © 2016 Qianqian Yang et al.This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided…”
BackgroundGonzález-Arancibia, F., Mamani, M., Valdés, C., Contreras-Matté, C., Pérez, E., Aguilera, J., Rojas, V., Ramírez-Malule, H., & Andler, R. (2024) · Biomolecules · doi:10.3390/biom14101224 · Cited by 23
Toepfer, S., Lackner, M., Keniya, M. V., & Monk, B. C. (2023) · Journal of Fungi · doi:10.3390/jof9020168 · Cited by 20
“CauErg11-6×His was partially purified from DM extracts of crude membranes using Ni-NTA affinity chromatography eluted with LHistidine [55].”
MethodRelationship between acyl-lipid and sterol metabolisms in diatoms
Maréchal, É., & Lupette, J. (2019) · Biochimie · doi:10.1016/j.biochi.2019.07.005 · Cited by 21
Azole Antifungal Sensitivity of Sterol 14α-Demethylase (CYP51) and CYP5218 from Malassezia globosa
Warrilow, A. G. S., Price, C. L., Parker, J. E., Rolley, N. J., Smyrniotis, C. J., Hughes, D. D., Thoss, V., Nes, W. D., Kelly, D. E., Holman, T. R., et al. (2016) · Scientific Reports · doi:10.1038/srep27690 · Cited by 19
Self-citationHosseini, P., Keniya, M. V., Sagatova, A. A., Toepfer, S., Müller, C., Tyndall, J. D. A., Klinger, A., Fleischer, E., & Monk, B. C. (2024) · Journal of Fungi · doi:10.3390/jof10120820 · Cited by 18
Singh, A., Paliwal, S., Sharma, M., Mittal, A., Sharma, S. K., & Sharma, J. P. (2015) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2015.10.014 · Cited by 21
Evolution-Based Protein Engineering for Antifungal Peptide Improvement
Gu, J., Isozumi, N., Yuan, S., Jin, L., Gao, B., Ohki, S., & Zhu, S. (2021) · Molecular Biology and Evolution · doi:10.1093/molbev/msab224 · Cited by 17
Price, C. L., Warrilow, A. G. S., Parker, J. E., Mullins, J. G. L., Nes, W. D., Kelly, D. E., & Kelly, S. L. (2015) · Applied and Environmental Microbiology · doi:10.1128/aem.03965-14 · Cited by 18
“cerevisiae CYP51 enzymes (15, 31, 32), suggesting a degree of variability with regard to substrate affinity among CYP51 enzymes.”
BackgroundSelf-citationXie, J., Zhu, L., Zhu, T., Jian, Y., Ding, Y., Zhou, M., & Feng, X. (2018) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.18-74 · Cited by 20
Sarı, S., Aslan, E. K., Kart, D., Özdemir, Z., Acar, M. F., Sayoğlu, B., Karakurt, A., & Dalkara, S. (2020) · International Microbiology · doi:10.1007/s10123-020-00144-y · Cited by 18
Alvarez-Rueda, N., Fleury, A., Logé, C., Pagniez, F., Robert, E., Morio, F., & Pape, P. L. (2016) · Medical Mycology · doi:10.1093/mmy/myw023 · Cited by 18
Antifungal Use in Veterinary Practice and Emergence of Resistance
Seyedmousavi, S., Wiederhold, N. P., Ebel, F., Hedayati, M. T., Rafati, H., & Verweij, P. E. (2018) · Springer eBooks · doi:10.1007/978-3-319-72093-7_16 · Cited by 16
Pharmacokinetic–pharmacodynamic optimization of triazole antifungal therapy
Lewis, R. E. (2011) · Current Opinion in Infectious Diseases · doi:10.1097/01.qco.0000399603.91138.e7 · Cited by 16
Keniya, M. V., Ruma, Y. N., Tyndall, J. D. A., & Monk, B. C. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01131-18 · Cited by 15
“Ni-NTA affinity-purified LDM6 His, used for spectroscopic assays, was eluted using affinity purification buffer containing 50 mM L-histidine instead of imidazole (41).”
MethodBi, Y., Guo, P., Liu, L., Chen, L., & Zhang, W. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1188461 · Cited by 17
“The inhibitor ketoconazole acts on sterol 14-α-demethylase (CYP51G1), a key regulatory enzyme for sterol biosynthesis (Warrilow et al., 2010).”
BackgroundMethodGuillon, R., Pagniez, F., Rambaud, C., Picot, C., Duflos, M., Logé, C., & Pape, P. L. (2011) · ChemMedChem · doi:10.1002/cmdc.201100262 · Cited by 12
Joaquim, A. R., Reginatto, P., Lopes, M. S., Bazana, L. C. G., Gionbelli, M. P., de Cesare, M. A., Kaminski, T. F. A., Teixeira, M. L., Abegg, M. A., Fuentefría, A. M., et al. (2021) · New Journal of Chemistry · doi:10.1039/d0nj06188c · Cited by 14
Zelenko, U., Hodošček, M., Rozman, D., & Grdadolnik, S. G. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500556k · Cited by 10
Graham, D. O., Wilson, R. K., Ruma, Y. N., Keniya, M. V., Tyndall, J. D. A., & Monk, B. C. (2021) · Journal of Fungi · doi:10.3390/jof7110897 · Cited by 13
“It has been suggested that FLC resistance due to the I471T mutation results from a combination of increased catalytic turnover, increased affinity for substrate, and a reduced affinity for FLC in the presence of substrate [40], but how this happens is not understood.”
BackgroundMethodInfluentialEfficacy of Flavonoids in Combating Fluconazole Resistant Oral Candidiasis
Srivastava, D., Yadav, A., Naqvi, S., Awasthi, H., & Fatima, Z. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220324140257 · Cited by 11
Bhagwat, S. K., Chobe, S. S., Alavala, R. R., Vora, A., More, R. A., Bobade, V. D., Patil, A. A., Pawar, T. J., Hernández-Rosas, F., & Patil, S. V. (2025) · RSC Advances · doi:10.1039/d5ra04254b · Cited by 17
Druggable Sterol Metabolizing Enzymes in Infectious Diseases: Cell Targets to Therapeutic Leads
Nes, W. D., Chaudhuri, M., & Leaver, D. J. (2024) · Biomolecules · doi:10.3390/biom14030249 · Cited by 10
Self-citationOgris, I., Zelenko, U., Sosič, I., Gobec, M., Skubic, C., Ivanov, M., Sokóvić, M., Kocjan, D., Rozman, D., & Grdadolnik, S. G. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104472 · Cited by 9
Candida albicans enhances iron uptake to maintain fluconazole resistance
Sharma, R., Nahar, A., & Puri, S. (2025) · Infection and Immunity · doi:10.1128/iai.00002-25 · Cited by 8
“3A) that is needed for fluconazole resistance suggests that lanosterol 14α-demethylase (Cyp51), an iron-requiring heme protein (31) involved in ergosterol biosynthesis, is upregulated (32).”
Allison, J. C., & Hyland, E. M. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1656723 · Cited by 15
Víglaš, J., & Olejníková, P. (2023) · Research in Microbiology · doi:10.1016/j.resmic.2023.104055 · Cited by 8
Xie, J., Zhu, L., Zhu, T., Jian, Y., Ding, Y., Zhou, M., & Feng, X. (2019) · Journal of Human Nutrition and Dietetics · doi:10.1111/jhn.12634 · Cited by 8
Zambom, C. R., da Fonseca, F. H., & Garrido, S. S. (2020) · Microorganisms · doi:10.3390/microorganisms8071024 · Cited by 9
“Some of the reported resistance mechanisms involve amino acid substitutions on the molecular targets of the antifungals—like that observed in the Fks subunits of glucan synthase, target of the echinocandins [79]—or in the enzyme 14-alpha demethylase, targeted by azoles [80,81].”
BackgroundGnedenko, O. V., Kaluzhskiy, L. A., Molnar, A. A., Yantsevich, А. V., Mukha, D., Gilep, A. A., Usanov, S. A., Stonik, V. A., Ivanov, A. S., Lisitsa, A., et al. (2013) · Biochemistry (Moscow) Supplement Series B Biomedical Chemistry · doi:10.1134/s1990750813030049 · Cited by 6
Sadeek, S. A., Zordok, W. A.-A., El-Farargy, A. F., & El‐Desoky, S. I. (2014) · Journal of the Korean Chemical Society · doi:10.5012/jkcs.2014.58.2.169 · Cited by 6
Turcan-Trofin, G.-O., Zaltariov, M., Roman, G., Shova, S. G., Vornicu, N., Bălan, M., Isac, D. L., Neamțu, A., & Cazacu, M. (2019) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2019.111560 · Cited by 6
Alsulaimany, M., Binjubair, F. A., Tatar, E., Kelly, D. E., Kelly, S. L., Warrilow, A. G. S., Keniya, M. V., Monk, B. C., Parker, J. E., & Simons, C. (2025) · RSC Medicinal Chemistry · doi:10.1039/d4md00863d · Cited by 5
Self-citationDeshkar, S. S., Vas, A., Pagar, R. R., Giram, P. S., Thomas, A. B., & Undale, V. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17050622 · Cited by 5
“The inhibition of the production of ergosterol further leads to the lysis of the fungal cell wall [16].”
Romo, J. A., Tomihiro, M., & Kumamoto, C. A. (2023) · mSphere · doi:10.1128/msphere.00122-23 · Cited by 6
“We focused on ERG11, which encodes Lanosterol 14-alpha-demethylase, a key enzyme in ergosterol biosynthesis (68), KNH1 encoding a product important in β1,6-glucan synthesis (69), MNN2 encoding an α-1,2-mannosyltransferase important for the glycosylation of cell wall components (70), FIG 4 C.”
BackgroundPrice, C. L., Warrilow, A. G. S., Rolley, N. J., Parker, J. E., Thoss, V., Kelly, D. E., Corcionivoschi, N., & Kelly, S. L. (2022) · PLoS ONE · doi:10.1371/journal.pone.0265227 · Cited by 7
Self-citationSaha, D., Gregor, J. B., Hoda, S., Eastman, K. E., Gutierrez-Schultz, V. A., Navarrete, M., Wisecaver, J. H., & Briggs, S. D. (2024) · mSphere · doi:10.1128/msphere.00524-24 · Cited by 4
Seyedmousavi, S. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc295 · Cited by 4
Susanti, L., Mustarichie, R., Halimah, E., & Kurnia, D. (2022) · RASAYAN Journal of Chemistry · doi:10.31788/rjc.2022.1516603 · Cited by 3
Transferosomes As A Promising Platform for Targeted Antifungal Drug Delivery
Jain, Y., Jain, G., Dutta, D., & Yadav, M. (2025) · Current Fungal Infection Reports · doi:10.1007/s12281-025-00510-1 · Cited by 4
“[ 76] Echinocandins (Caspofungin, Micafungin, Anidulafungin and Rezafungin) • These cyclic hexapeptides disrupt the enzyme [1,3]-β-D-glucan synthase, which is necessary for cell wall production.”
Cristea, A., Iancu, A. V., Tatia, R., Gioia, M. L. D., Ștefan, C. S., Dragostin, I., Lisă, E. L., & Dragostin, O.-M. (2026) · Processes · doi:10.3390/pr14030409 · Cited by 3
Conazoles and Cancer: A Review
Nesnow, S. (2016) · Royal Society of Chemistry eBooks · doi:10.1039/9781782624059-00280 · Cited by 2
In Silico Inhibition of Essential Candida albicans Proteins by Arenicin, a Marine Antifungal Peptide
Silva, L. D. C., Barbosa, A. M., Tannous, I. P., Santos, T. G., de Curcio, J. S., Oliveira, L. N., Silva, M. G., de Oliveira, A. A., Lima, R. M., & Silva, K. S. F. E. (2019) · International Marine Science Journal · doi:10.14302/issn.2643-0282.imsj-18-2448 · Cited by 2
Metadata
- Authors
- Warrilow, A. G. S., Martel, C. M., Parker, J. E., Melo, N., Lamb, D. C., Nes, W. D., Kelly, D. E., & Kelly, S. L.
- Affiliations
- Swansea University (GB)
- Texas Tech University (US)
- Corresponding author
- Kelly, Steven L.
- ORCID
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2010-10
- Volume
- 54
- Issue
- 10
- Pages
- 4235-4245
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC2944560
- OpenAlex
- W2101970140
- Cited by
- 112
- References
- 60
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 7 · 2023: 5 · 2022: 7 · 2021: 7 · 2020: 6 · 2019: 9 · 2018: 8 · 2017: 7 · 2016: 11 · 2015: 4 · 2014: 8 · 2013: 9 · 2012: 6
- FWCI
- 5.13
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Keywords
- Candida albicans, sterol 14α-demethylase, CYP51, lanosterol, fluconazole, itraconazole, voriconazole, ketoconazole, clotrimazole, econazole, miconazole, CO displacement, enzyme kinetics, antifungal resistance, fluconazole resistance, antifungal drug screening
- MeSH terms
- Antifungal Agents, Azoles, Candida albicans, Econazole, Ketoconazole, Miconazole, Protein Binding, Pyrimidines, Triazoles, Fluconazole, Itraconazole, Sterol 14-Demethylase, Voriconazole
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.